Allos Therapeutics, Inc. (Nasdaq: ALTH) announced top line results from ENRICH, the Company\'s pivotal Phase 3 study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE